The potential of stem cell research is seemingly unlimited. With this tool, scientists and clinicians are able to focus not just on finding better treatments but also on finding cures for many of the diseases ailing the world today, including heart disease, neurodegenerative diseases, and metabolic diseases such as diabetes. Modern medical science is finally bringing together the intellectual forces of international academic researchers, industry scientists, and clinicians. Such collaborations are of high relevance for emerging science such as stem cell research, which hold great potential for therapeutics and understanding of development and diseases. This sense of collaboration was prominent at the First International Stem Cells & Regenerative Medicine – 2006 Meeting held by GeneExpression Systems in San Francisco, USA in January, which recognized the promise of stem cells and profiled key advancements in various areas of stem cell research. This 3-day meeting brought together industry leaders and entrepreneurs, renowned international scientists from high caliber academic institutions, and even some government representatives, contributing seminars, posters, and product presentations displaying the latest tools in stem cell research. Attendees to this inaugural meeting were greeted with a letter from Governor Arnold Schwarzenegger endorsing the conference, which began with lectures by Nobel Laureate (1980, Chemistry) Dr Paul Berg (Stanford University, Stanford, CA) and by Dr Gail Martin, (University of California, San Francisco, CA, USA). Dr Berg’s presentation covered the saga of pushing stem cell research to the forefront of science, in particular by working with policy makers both at the state and national level in order to gain ‘political justification’. He compared the present stem cell research battle with the mid-1970s recombinant DNA scenario, and is optimistic that stem cell research will be useful for the benefit of human kind, if certain guidelines are followed. Dr Martin covered the historical aspects of stem cell research, speaking from an embryological and developmental biology perspective. She narrated the ‘road to embryonic stem cells and beyond’ beginning with the 1960s and the work of Leroy Stevens from the Jackson labs, who discovered ‘embryonal carcinoma’ cells whilst studying testicular teratocarcinomas. Later Stevens and colleagues demonstrated that these embryonal carcinoma cells are indeed ‘pluripotent stem cells’. In the mid-1970s Dr Martin’s postdoctoral work with Dr Evans at the University of Cambridge, UK led her to develop new and in vitro clonal culture methods of embryoid cells. In the early 1980s she and Evans independently isolated stem cells from mouse embryos and coined the term ‘embryonic stem cells.’ Martin also highlighted the work of Dr Jamie Thompson of the University of Wisconsin, who was successful in culturing the human embryonic stem cell lines during the mid-1990s. Presentations throughout the meeting covered an array of topics staying true to the meeting’s subtitle, Molecular Embryology to Tissue Engineering & Therapeutics.
Read full abstract